Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification

29 Mar 2024

Abstract excerpt

BACKGROUND: Despite the extensive study of MYCN-amplified neuroblastomas, there is a significant unmet clinical need in MYCN non-amplified cases. In particular, the extent of heterogeneity within the MYCN non-amplified population is unknown. METHODS: A total of 1566 samples from 16 datasets were identified in Gene Expression Omnibus (GEO) and ArrayExpress. Characterisation of the subtypes was analysed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Chromatin Remodeling and Cancer
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38553589
DOI: 10.1038/s41416-024-02666-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratificationPMID 38553589Read ↗

Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratificationSemantic proximity Read ↗

Stratified Immune Profiling Uncovers Prognostic Heterogeneity Beyond MYCN Amplification and Age in NeuroblastomaSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read ↗

Bioinformatic analysis of the inner heterogeneity within MYCN non-amplified pediatric neuroblastoma sub-groupSemantic proximity Read ↗

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN -Not-Amplified Human NeuroblastomaSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.Semantic proximity Read ↗

High-risk, Expression-Based Prognostic Long Noncoding RNA Signature in NeuroblastomaSemantic proximity Read ↗

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastomaSemantic proximity Read ↗

High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastomaSemantic proximity Read ↗

MYCN in Neuroblastoma: “Old Wine into New Wineskins”Semantic proximity Read ↗

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.Semantic proximity Read ↗

Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.